Company profile
NiKang Therapeutics, Inc.
Privately held: no public share price (Wilmington, DE-based clinical-stage oncology biotech founded 2017; venture-backed with ~$260M raised across Series A-C rounds from HBM Healthcare Investments, Casdin Capital, Octagon Capital and others. No IPO filed or completed; remains privately held. (Third-party 'pre-IPO share' marketplaces like Forge/Linqto/notice.co list speculative secondary-market pricing, not an actual public listing.) Sources: https://clinicaltrials.gov/study/NCT07029399 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://technical.ly/startups/nikang-therapeutics-series-c/ ; https://tracxn.com/d/companies/nikang-therapeutics/__QQr5Ge3jstenG-bd2AwJ4-BE_duMAtTZI_ujoLyho7Q Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | CDK2/CDK4Small molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.